CRSP

CRISPR Therapeutics AG

Add to Watchlist

Advanced Chart

65.930

+0.6(0.918%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

66.770

Open

64.682

VWAP

64.47

Vol

4.21M

Mkt Cap

5.69B

Low

61.1338

Amount

271.11M

EV/EBITDA(TTM)

Total Shares

84.92M

3.77B

EV/OCF(TTM)

P/S(TTM)

147.62

CRISPR Therapeutics AG is a Switzerland-based gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) and is a technology for gene editing, the process of precisely altering specific sequences of genomic DNA. The Company aims to apply this technology to disrupt, delete, correct and insert genes to treat genetically-defined diseases and to engineer advanced cellular therapies. The Company has acquired the rights to the intellectual property (IP) encompassing CRISPR/Cas9 and related technologies and is also involved in its own IP research and additional in-licensing efforts. The Company product development and partnership strategies are designed to exploit the full potential of the CRISPR/Cas9 platform while maximizing the probability of successfully developing their product candidates.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2025Q3

FY2025Q2

23.45M

-34.3%

-1.141

+159.31%

12.23M

+1931.34%

-1.299

+28.62%

6.44M

+1145.8%

-1.438

-3.46%

Estimates Revision

The market is revising Downward the revenue expectations for CRISPR Therapeutics AG (CRSP) for FY2025, with the revenue forecasts being adjusted by -17.42% over the past three months. During the same period, the stock price has changed by 71.07%.

Revenue Estimates for FY2025

Revise Downward

-17.42%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+7.16%

In Past 3 Month

Stock Price

Go Up

+71.07%

In Past 3 Month

21 Analyst Rating

5.32% Upside

Wall Street analysts forecast CRSP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CRSP is 69.44 USD with a low forecast of 35.00 USD and a high forecast of 105.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

14 Buy

7 Hold

0 Sell

Moderate Buy

5.32% Upside

Current: 65.930

Low

35.00

Averages

69.44

High

105.00

5.32% Upside

Current: 65.930

Low

35.00

Averages

69.44

High

105.00

Clear Street

Bill Maughan

Buy

Hold

downgrade

$45

2025-06-27

Reason

Clear Street

Bill Maughan

Price Target

$45

2025-06-27

downgrade

Buy

Hold

Reason

Barclays

Equal Weight

downgrade

$56 -> $42

2025-05-09

Reason

Barclays

Price Target

$56 -> $42

2025-05-09

downgrade

Equal Weight

Reason

Barclays lowered the firm's price target on Crispr Therapeutics to $42 from $56 and keeps an Equal Weight rating on the shares. The company's Q1 update highlighted promising initial CTX310 Phase 1 data, the analyst tells investors in a research note.

Needham

Gil Blum

Strong Buy

Reiterates

$84

2025-04-09

Reason

Needham

Gil Blum

Price Target

$84

2025-04-09

Reiterates

Strong Buy

Reason

Cantor Fitzgerald

Eric Schmidt

Hold

Reiterates

n/a

2025-02-19

Reason

Cantor Fitzgerald

Eric Schmidt

Price Target

n/a

2025-02-19

Reiterates

Hold

Reason

Citigroup

Yigal Nochomovitz

Strong Buy

Maintains

$89 → $82

2025-02-18

Reason

Citigroup

Yigal Nochomovitz

Price Target

$89 → $82

2025-02-18

Maintains

Strong Buy

Reason

Morgan Stanley

Terence Flynn

Sell

Maintains

$30 → $32

2025-02-14

Reason

Morgan Stanley

Terence Flynn

Price Target

$30 → $32

2025-02-14

Maintains

Sell

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for CRISPR Therapeutics AG (CRSP.O) is -12.98, compared to its 5-year average forward P/E of -13.68. For a more detailed relative valuation and DCF analysis to assess CRISPR Therapeutics AG 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-13.68

Current PE

-12.98

Overvalued PE

10.32

Undervalued PE

-37.69

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-6.84

Current EV/EBITDA

-9.82

Overvalued EV/EBITDA

11.47

Undervalued EV/EBITDA

-25.15

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

315.76

Current PS

100.50

Overvalued PS

759.05

Undervalued PS

-127.52